Structural basis of cysteine biosynthesis and peptidoglycan remodelling in Mycobacterium tuberculosis by Böth, Dominic
 
Division of Molecular Structural Biology 
Department of Medical Biochemistry and Biophysics 
Karolinska Institutet, Stockholm, Sweden 
 
Structural Basis of Cysteine 
Biosynthesis and 
Peptidoglycan Remodelling 
in Mycobacterium 
tuberculosis 
Dominic Böth 
 
 
Stockholm 2014 
 
 
 
All previously published papers were reproduced with permission from the publisher. 
 
Published by Karolinska Institutet. Printed by Åtta.45 Tryckeri AB 
 
© Dominic Böth, 2013 
ISBN 978-91-7549-388-6
  
ABSTRACT 
 
Mycobacterium tuberculosis is the causative agent of tuberculosis, which is responsible 
for 1.3 million deaths annually. Treatment is difficult due to an elaborate defense 
machinery, which includes specific metabolic changes of the bacilli upon exposure to 
antibiotics and the immune response of the host. The emergence of multi-drug-resistant 
and extremely drug-resistant strains further complicates the treatment. Therefore the 
development of novel antibiotics and the investigation of new unexploited targets are of 
high importance. In the scope of this work, potential drug targets from the L-cysteine 
biosynthesis and the mycobacterial cell envelope maintenance were investigated. 
 
Cysteine biosynthesis provides promising drug targets due to a direct connection 
between L-cysteine availability and redox homeostasis of the bacilli. Disruption of the 
mycobacterial redox defense leads to attenuated growth. Three cysteine synthases are 
encoded in the mycobacterial genome of which CysK1 and CysM have been 
characterized previously. In this work CysK2 has been enzymatically characterized, 
catalyzing the formation of L-cysteine from O-phosphoserine and sulfide in a 
pyridoxal-5-phosphate-dependent reaction.  
 
The importance of the cell wall integrity makes it a well exploited target of a broad 
range of antibiotics. Potent inhibitors and first-line antibiotics are currently in clinical 
use such as isoniazid and ethambutol, which target biosynthetic pathways of the 
mycobacterial cell wall. RipA, a protein of the NlpC/p60 family was previously 
validated as essential for infectivity. The characterized NlpC/p60 proteins are 
peptidoglycan hydrolases and are involved in cell division and peptidoglycan recycling. 
In M. tuberculosis, four proteins represent this family: RipA, RipB, RipC and RipD. 
Here we report the biochemical and biophysical characterization of RipA, RipB and 
RipD as well as their high resolution structures. The detailed understanding of these 
enzymes prepares the ground for structure-based inhibitor development targeting this 
enzyme family. RipA and RipB hydrolyze the peptidoglycan peptide stem between D-
glutamyl- and meso-diaminopimelic acid residues. RipD is the first NlpC/p60 protein, 
which adapted to a non-catalytic peptidoglycan-binding function and most likely acts as 
a scaffold or regulatory protein. 
 
The integrity and stability of the peptidoglycan layer is vital for intracellular survival of 
M. tuberculosis. L,D- and D,D-transpeptidases strengthen the peptidoglycan layer to 
withstand chemical and physical stress by the formation of 3-3 and 3-4 cross-links, 
respectively. The genome of M. tuberculosis encodes five orthologues, the L,D-
transpeptidases LdtMt1-5. The three-dimensional structure of LdtMt2 consists of three 
domains: two smaller domains of the Ig-fold-type segments of the protein (A and B 
domain) and the transpeptidase domain (C domain). The structure of the two fragments 
AB domain and BC domain, which are comprising the entire periplasmic part of the 
enzyme, gives insights to the arrangement of the peptidoglycan layers in the 
mycobacterial cell wall. Additionally, LdtMt2 has been identified as an off-target for β-
lactam antibiotics by the formation of acyl-enzyme complexes with penam and penem 
class β-lactams. 
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1. MYCOBACTERIUM TUBERCULOSIS 
 
During the last two decades, tuberculosis (TB) has been recognized as a major global 
health problem since it is one of the leading causes of death among infectious diseases 
worldwide. The WHO estimated the total number of new infections with 8.7 million 
and recorded 1.3 million reported deaths of which about 300.000 have been HIV-
associated TB deaths in 2012. In 1993, the WHO implemented a five component 
package as a strategy to contain TB comprising political commitment, proper 
diagnostics, supply of first line antibiotics, pursuit of communication and social 
mobilization to facilitate the report within the national TB control programs (NTPs) and 
program-based operation research. Geographically, the highest incidence rates are 
reported and estimated in Africa and Asia (Figure 1). About 40% of all TB cases can be 
located to China and India; however, the highest rates of cases and deaths per capita are 
in sub-Saharan Africa. About 0.5 million cases and 74.000 deaths are extrapolated in 
the group of children younger than age of 15. In 2011, 5.8 million newly diagnosed 
cases were reported to the NTPs. After administration of first line medication, a 
treatment success in 85% of the patients has been documented globally1. Worldwide, 
about 20% of TB-positive patients are estimated to be infected with multi-drug-
resistant TB (MDR-TB). 
 
 
 
Figure 1: Map indicating the estimated number of new TB cases worldwide according to the Global 
Tuberculosis Report 20131 
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1.1 ACTIVE AND LATENT FORM OF THE TUBERCULOSIS DISEASE 
 
Mycobacterium tuberculosis has been first discovered by Robert Koch as the causative 
agent of TB, which typically affects the lungs, but also other organs. The expulsion of 
bacteria from TB-positive patients spread the disease; however only a smaller number 
of patients infected with M. tuberculosis is developing active TB. 
Primary TB is pulmonary, but the bacilli can disseminate within the host when left 
untreated. The common way of transmission of mycobacteria is airborne, to date the 
exact dose for a spread resulting in disease development is unclear2,3. Active TB is 
usually characterized by an initial lung inflammation followed by the phagocytosis of 
the bacilli by alveolar macrophages. If no treatment is administered, the disease leads to 
death. Commonly, a cluster of infected macrophages start to form multi-nucleated 
Langerhans cells in the lung parenchyma followed by a specific immune response, 
which initiates the formation of granuloma coinciding with a self-destructive formation 
of lesions in the lung4,5. In terminal stages of the active infection, tissue damage 
aggravates and leads to expulsion of bacilli by coughing. 
A M. tuberculosis-specific immune response in absence of a clinical manifestation of 
the disease defines the state of a latent TB infection (LTBI)6. M. tuberculosis enters 
lung tissue and persists in primary phagosomes of alveolar macrophages by arresting 
phagosome maturation7. During LTBI, the immune system of the host is able to contain 
the bacilli by rendering them in a non-replicative state, but the host is unable to clear 
the infection. The formation of productive granulomas follows, which is common in 
LTBI. They are originating from interaction of naïve T cells with infected 
macrophages8,9. Antigens from M. tuberculosis are processed by antigen-presenting 
cells, which in turn lead to a specific immune response, but not to a complete clearance. 
Recommended standard for the reliable diagnosis of TB are the sputum microscopy and 
the culture in liquid medium. Commonly, drug susceptibility tests are conducted in 
parallel. As a more cost-effective method, solid culture media are suggested and 
frequently used in resource poor countries10. PCR screening, imaging and 
immunohistochemical examination of biopsy samples support the diagnosis of active 
TB11. An estimate of 30% of TB-positive patients and about 90% of MDR-TB-positive 
patients remain undiagnosed in low income countries1. 
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1.2 FIRST LINE DEFENSE – MACROPHAGES AND NEUTROPHILS 
 
It could be experimentally shown that the fort mechanism of immune response 
following an infection of the airways is the diapedesis of phagocytic cells including 
alveolar macrophages, dendritic cells and neutrophils. The phagocytes engulf the bacilli 
and contribute to the first line of defense by the expression of antimicrobial peptides 
(Figure 2)12–16. The phagocytes orchestrate the action of the other components of the 
immune system via cytokine production. Macrophage and neutrophil response is 
therefore critical for the outcome of the immune response to mycobacteria, which could 
either promote bacterial clearance or containment, the latter resulting in the 
development of LTBI17,18. 
M. tuberculosis mediates macrophage signaling via scavenger receptors, complement 
receptors and mannose receptors, leading to the formation of the phagosome19. In the 
case of nonviable mycobacteria, phagolysosomal fusion occurs (e.g. upon IFN-γ 
signaling) and the bacilli are lysed. On the contrary, viable and virulent M. tuberculosis 
prevents the phagosome from maturation: a fusion of the phagosomal and the 
lysosomal compartment is impeded and bacterial clearance fails8,13. Dissemination of 
bacteria thereafter results in the activation of a T cell response in the lung-draining 
mediastinal lymph nodes (Figure 3). 
M. tuberculosis can induce necrotic cell death within the macrophages, which allows 
the bacilli to be released from the cell and spread (Figure 2). A very potent alternative 
protective mechanism of the macrophage is the single cell apoptosis as well as contact-
dependent apoptosis leading to the delivery of the compartmentalized bacilli along with 
the apoptotic debris to the lysosome in which the bacteria are killed; a process called 
efferocytosis20,21. Efferocytosis further supports the process of sequestration of 
compartmentalized bacteria and subsequent clearance22 (Figure 2). Mycobacteria 
however display virulence mechanisms which inhibit the induction of apoptosis23,24. 
SecA2 has been identified as a key player in the inhibition of apoptosis. The gene 
encodes for a component of a virulence-associated protein secretion system. Deletion of 
secA2 results in enhanced apoptosis and increased priming of antigen-specific CD8+ 
and CD4+ T ells24. 
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Figure 2: Schematic representation of the cellular defense mechanisms of the host within the lung tissue. 
M. tuberculosis is engulfed by dendritic cells (DCs), macrophages (MΦ) and neutrophils. DCs activate 
naïve T cells upon IL-12 signaling, which do enter the site of infection thereafter to induce inflammation. 
The fate of MΦ is dependent on the signaling of PEG2, which promotes apoptosis, which in turn leads to 
efferocytosis and a subsequent killing of bacilli. MΦ necrosis leads to the dissemination of the bacilli. 
Neutrophils can also undergo apoptosis and necrosis, the exact signaling however remains elusive. 
Infected MΦ and neutrophils activate the synthesis of antimicrobial peptides as well as various cytokines. 
 
The type of cell death of macrophages, apoptosis or necrosis, is regulated by 
eicosanoids, prostaglandin E2 (PGE2) and lipoxin A4 (LXA4). By induction of LXA4 
and repression of PGE2, mycobacteria evoke necrosis and apoptosis is avoided, 
resulting in cell-to-cell spread of bacteria (Figure 2). Alveolar macrophages of Alox5-/- 
mice infected with M. tuberculosis display the tendency to undergo apoptosis25,26. In 
parallel to the antimicrobial action of macrophages, neutrophils fulfill a detrimental role 
in pathogenesis of TB. They facilitate activation of naïve antigen-specific CD4+ T cells 
during the course of infection and promote the adaptive immune system by direct 
interaction with DCs, which in turn are more effective activators of CD4+ T cells. 
Neutrophils activate immune signaling via IL-6 and IL-17; the IFN-γ signaling 
however remains unaffected27. 
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1.3 FORMATION OF GRANULOMAS AS A RESULT OF HUMAN IMMUNE 
RESPONSE 
 
The exact role of granuloma formation during an infection with M. tuberculosis is not 
known. It is suggested that granulomas participate in the protection of the host against 
an uncontrolled spread of bacilli, on the other hand their contribution to tissue 
pathology is discussed and even the promotion of infection has been imputed27. 
However, the different stages of the granuloma seem to depend on the progression of 
disease and immune response. Innate and adaptive immunity control the morphology of 
granulomas8,9,28. 
The tubercular granulomas contain infected macrophages in their center, which have 
differentiated into multi-nucleated giant cells, epithelioid cells, foamy macrophages 
harboring lipid droplets and neutrophils29. This core is surrounded by lymphocytes 
(CD4+ and CD8+ T cells and B cells) and fibroblasts, which produce the peripheral 
fibrotic capsule. Proinflammatory and inhibitory cytokines play a key role in the 
formation of granulomas27,30. 
The presence of the necrotic core appears as a secondary result to cell lysis and creates 
a hypoxic hostile environment. The same types of granulomas have also been found in 
infected guinea pigs and nonhuman primates used as model organisms, but not in 
mice31. In LTBI, bacilli reside within the central hypoxic environment where they 
undergo drastic metabolic changes. In the situation of an active infection, replication of 
the bacilli occurs mainly in the oxygenated areas28. It has been proposed that 
mycobacteria create a supportive environment within the granuloma e.g. through 
manipulation of the macrophage lipid metabolism29.  
 
1.4 ANTIBIOTIC TREATMENT AND DRUG RESISTANCE 
 
Despite evolutionary pressure, aggravation of drug-resistant TB is to a large extent the 
result of interrupted or inadequate TB therapy. It threatens global efforts to control the 
global TB epidemic and is a major concern of public health in several countries. MDR-
TB is defined by resistance against two of the most commonly administered antibiotics, 
isoniazid (INH) and rifampicin (RIF). According to the WHO, the rates of new MDR-
TB cases are highest in Eastern Europe and Russia. About 20% of the new cases are 
diagnosed as MDR-TB. The total number of MDR-TB cases however is estimated for 
India and China, which account for almost 40% of all MDR-TB cases worldwide. 
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Extensively drug-resistant TB (XDR-TB) displays resistance against all members of the 
fluoroquinolones and at least one of the three injectable second line drugs in addition to 
INH and RIF1,32,33. 
 
 
 
 
Figure 3: First-line antibiotics used for short course treatments. (a) Isonicotinylhydrazine (Isoniazid, 
INH), (b) Pyrazinamide (PZA), (c) Ethambutol (EMB), (d) Rifampicin (RIF) 
 
In general, drug-resistance occurs due to chromosomal mutations in a low proportion of 
M. tuberculosis in pan-sensitive strains. Combined drug treatment is meant to prevent 
the emergence of drug-resistant bacteria. The first positive effect of combined drug 
administration has been seen in combination therapy of M. tuberculosis with 
streptomycin and p-aminosalicylic acid (PAS). Emergence of streptomycin-resistance 
could be largely prevented in presence of PAS34,35. After the introduction of INH, PAS 
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has quickly been replaced, followed by regimens of INH and streptomycin. In 1960, 
after emergence of drug-resistance against INH, PAS or streptomycin, a triple therapy 
for at least 12 months with all three became standard treatment in Europe. Almost half 
of the patients failed to complete the treatment36. Modern short course treatments were 
possible after the development of RIF and PZA. This regimen gives four drugs: INH, 
RIF, PZA and EMB37,38 (Figure 3). The simultaneous use of several drugs in 
combination contained drug-resistance remarkably. Non-continuous drug 
administration, treatment interruptions as well as changes in treatment based on side 
effects, pharmacokinetic interactions and inconstancy in compliance result in 
mechanisms, which allow the emergence of drug resistance39. Recently, also totally 
drug-resistant TB has been described1,40,41. To meet this problem, new effective drugs 
and the identification of potent drug targets are required42.  
In view of this alarming situation, much of the current research about M. tuberculosis is 
focused on host-pathogen interaction including the complex immune answer upon 
mycobacterial infection as well as the development of vaccines and potent novel drugs 
to contain the bacilli from an epidemic spread. The identification of new target proteins 
or essential genes, which in turn can be targeted with potent antibiotics exhibiting new 
mechanisms of action, is of high relevance. Structure-based drug discovery, phenotypic 
screening and detailed biochemical understanding will aid on this route. 
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2. OXIDATIVE STRESS – SMALL MOLECULES AS 
POTENT ROI/RNI SCAVENGERS 
 
During infection and transmission, M. tuberculosis encounters oxidative stress. During 
LTBI, bacilli are residing in granulomas of alveolar macrophages, where they are 
confronted with hypoxic stress and nutritional deprivation31,43. 
 
2.1 REDOX HOMEOSTASIS 
 
Maintenance of a redox balance is crucial for every organism; catabolic and anabolic 
processes need to effectively be separated from each other. Elaborate machineries 
counteracting redox stress imposed by macrophages are necessary to maintain redox 
homeostasis. Five well characterized redox couples play a key role: NADH/NAD+, 
NADPH/NADP+, mycothiol, thioredoxins and peroxiredoxins. Under normoxic 
conditions, the NADH/NAD+ ratio is favoring high levels of NAD+ for efficient 
electron extraction through catabolic reactions44. Under hypoxic conditions however, 
the ratio changes by an accumulation of NADH, suggesting reductive stress during 
pathogenesis44, which also leads to resistance against INH45. Inhibition of reoxidation 
of NADH/FADH2 results in a disruption of redox homeostasis and inhibits bacterial 
growth. 
One can distinguish two sources of oxidative stress M. tuberculosis encounters: 
endogenous and exogenous stress. Endogenous stress is characterized by endoxidation 
of carbon chains using O2 as the final electron acceptor involving one-electron transfer 
in the respiratory chain as well as stress induced by bactericidal drugs. Exogenous 
stress is generated by the immune response of the host. Macrophages and neutrophils 
are producing ROI and RNI. The formation of a superoxide radical (O2-∙) can serve as a 
precursor of RNI46,47. The generation of O2-· is catalyzed by a single electron reduction 
of O2 by the NADPH oxidase e.g. in macrophages and neutrophils. H2O2 is produced 
by a reaction of two O2-· catalyzed by superoxide dismutase, which in turn can react to 
highly reactive hydroxyl radicals (HO·) through a Fenton reaction48. It has been 
suggested that a number of bactericidal antibiotics act along the formation of HO·49, 
this however has been questioned recently by experimental data excluding a correlation 
of antibiotic treatment and ROI production5051.  
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ROI and RNI have been shown to potently kill several pathogenic species, including 
various mycobacterial strains, where H2O2 and O2-· are the most abundant ROI. 
However, the exact role of ROI in M. tuberculosis remains elusive52–54. On the other 
hand, the role of RNI in TB is more defined by effectively killing M. tuberculosis in 
vitro55. Murine macrophages and epithelial alveolar lung cells express iNOS and 
produce significant levels of nitric oxide (NO) capable of killing mycobacteria56–58. 
Interestingly, NO is also a signal for the bacterium to enter dormancy, by inhibiting 
respiration and growth59. 
M. tuberculosis exhibits a sophisticated mechanism of sensing redox stress. In place of 
classical sensors like FNR, OxyR or SoxR, which are absent in the mycobacterial 
genome, it encodes for DosRST. The DosRST genes have been shown to be 
approximately 50-fold up-regulated in hypoxic conditions60–62. Besides oxygen 
depletion, the regulon is also activated by NO and carbon monoxide (CO) inside host 
lesions59,63,64. DosR has been characterized further as the transcriptional master 
regulator for dormancy and is controlled by the two histidine kinases DosS and DosT, 
which in turn are detectors of the impairment of respiration62,65,66. The transcription 
factor WhiB has been identified as a potent redox sensor. WhiB harbors an O2-∙‐ and 
NO-responsive iron/sulfur cluster and is a major player in coordinating the metabolic 
response of M. tuberculosis upon changes in redox homeostasis67,68. 
 
2.2 SUSTAINING THE THIOL-REDOX STATUS IN M. TUBERCULOSIS 
 
Thiol compounds are providing the redox control in all living organisms. A balanced 
thiol pool is also vital for M. tuberculosis to survive within the host. The reductive 
milieu of the cytosol of the bacilli is maintained by multiple thiol buffers, which can 
occur in millimolar concentration69. The primary reducing systems are based on 
mycothiol (MSH), a disaccharide, which is equivalent to glutathione (GSH), and the 
thioredoxin (Trx) system. 
 
2.2.1 MSH 
 
In nature, GSH is the most abundant low-molecular-weight thiol compound (Figure 4). 
Most actinobacteria however deploy MSH instead of GSH. MSH consists of 
glucosamine, myo-inositol and N-acetylcysteine and is the major low molecular weight 
thiol compound in M. tuberculosis (Figure 4). MSH biosynthesis is therefore dependent 
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of L-cysteine synthesis70. Under ROI and RNI stress, MSH is necessary to maintain 
survival of M. tuberculosis71,72. MSH funnels the reaction cycle by reducing a reaction 
partner under formation of a mixed disulfide. Oxidized MSH is thereafter reduced by 
mycothiol reductase in a NADPH-dependent reaction. Only recently, mycoredoxins 
catalyzing the reduction of oxidized MSH have been found in mycobacteria and 
subsequently in other actinobacteria73. The de novo synthesis of MSH requires 5 steps: 
The initial reaction is the formation of the glycoside bond between N-
acetylglucopyranosyl-inositol phosphate, which is subsequently dephosphorylated and 
deacetylated, followed by the condensation of L-cysteine and the subsequent 
acetylation of the L-cysteine to form active MSH74 (Figure 4). The MSH biosynthetic 
pathway has been recognized as a promising drug target, since it is unique for 
actinobacteria and essential for growth and survival of M. tuberculosis71,72. First 
inhibitors have been developed following a structure-based approach against the 
enzyme MshC, which catalyzes the condensation of L-cysteine to the disaccharide75,76. 
In M. tuberculosis, MSH is present at millimolar concentrations. Interestingly, bacilli 
void of MSH after knock-out of MshC upregulate the biosynthesis of the thiourea 
derivative ergothioneine, which is involved in the redox balance77,78. 
 
 
 
Figure 4: Mycothiol as a potent radical scavenger in M. tuberculosis. It consists of a disaccharide 
condensed to an acetylated L-cysteine residue. The thiol group of the cysteine represents a reduced sulfur 
species important for redox homeostasis. 
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2.2.2 Thioredoxin 
 
Thioredoxins (Trxs) have been characterized as systemic disulfide reductases 
sustaining a reductive environment. Trxs cycle between a reduced and an oxidized state 
and show a conserved  WCXXC motif79,80. Oxidized Trxs are reduced by thioredoxin 
reductase (TrxR) in a FAD- and NADPH-dependent reaction81. M. tuberculosis codes 
for TrxA, TrxB and TrxC82, which have been shown to be non-essential83, indicating 
the redundancy of the system. In contrast, TrxR is essential and distinct from the 
mammalian enzyme and could therefore be an important drug target84. Peroxiredoxins 
(Prxs) have been linked to the electron transfer from Trxs85,86 and function as 
scavengers for hydroperoxides and peroxynitrites. 
 
2.3 SULFUR METABOLISM IN M. TUBERCULOSIS 
 
Bacteria of the Actinomycetales group produce mycothiol, a L-cysteine containing 
disaccharide as a potent radical scavenger for maintenance of redox homeostasis70. This 
links the availability of cysteine and therefore reduced sulfur species directly to the 
redox defense of M. tuberculosis. As a response to redox stress during LTBI, genes 
involved in sulfur and cysteine metabolism have been shown to be upregulated87–89, 
which could be validated by a mutagenesis screen based on transposon insertions into 
genes related to cysteine metabolism leading to phenotypes more susceptible to defense 
mechanisms of the host cell83,90. 
The biosynthesis of sulfur-containing compounds is tightly connected to the sulfur 
assimilation pathway91, which is a pathway catalyzing the uptake and the metabolism 
of sulfate from the host92. Sulfate ,which enters the bacterial cell via an active transport 
is subsequently adenylated by the ATP sulfurylase CysD (Rv1285) / CysN (Rv1286), 
resulting in the formation of adenosine 5’-phosphosulfate (APS), which can either be 
directly reduced leading to sulfite (SO32-) and AMP by the APS reductase CysH 
(Rv2391)93 or phosphorylated by the APS kinase (Rv1286; C-terminal domain) to form 
3’-phosphoadenosine-5’-phosphosulfate (PAPS). PAPS is an abundant sulfate donor of 
sulfotransferases that produce metabolites like sulfolipid-194. The sulfite derived from 
the reductive branch of the APS/PAPS pathway is further reduced by SirA (NirA, 
Rv2391) to hydrogen sulfide (H2S) representing the sulfur source for reduced sulfur 
metabolites. Key enzymes involved in the cysteine biosynthetic pathways are SirA, a 
ferredoxin-dependent sulfite reductase, CysK1 (OASS-A; Rv2334)95, a pyridoxal-5-
 12 
phosphate (PLP)-dependent O-acetylserine (OAS) sulfhydrylase96, CysM (Rv1336)97 
and CysK2 (Rv0848), both O-phospho-L-serine (OPS)-dependent cysteine synthases 
(Figure 5), CysE (Rv2335), which catalyzes the formation of OAS, substrate for CysK1 
from serine in a CoA-SH-dependent reaction98 and CysO as sulfur donor for the CysM-
catalyzed reaction97,99 (Figure 5). 
 
2.3.1 SirA (Rv2391) 
 
SirA catalyzes a six-electron reduction of sulfite to sulfide (S2-) providing the reduced 
sulfur for sulfur-containing amino acids95. Thus, SirA allocates the necessary sulfide 
derived from the sulfur assimilation pathway for the OAS-dependent cysteine de novo 
synthesis. The enzyme was annotated as a ferredoxin-dependent sulfite/nitrite 
reductase; both substrates are accepted by the enzyme depending on the metabolic state 
of M. tuberculosis. Enzymes of this family contain a combination of a [Fe4-S4] 
iron/sulfur cluster and a siroheme and exhibit ~20% sequence identity to NADPH-
dependent sulfite reductases, e.g. found in E. coli and are usually monomeric, while the 
E. coli homologue forms an oligomeric complex95. 
 
 
Figure 5: The biosynthetic pathways for the de novo cysteine synthesis in M. tuberculosis. The canonical 
pathway is dependent on CysE and CysK1, which catalyze the synthesis of cysteine from serine via OAS 
and sulfide. The alternative pathway is catalyzed by CysM. This pathway requires the availability of OPS 
as acceptor substrate and thiocarboxylated CysO-SH as sulfur donor. The third pathway is based on 
CysK2, characterized in this work. The substrate preference reflects a combination of CysK1 and CysM. 
CysK2 utilizes OPS as acceptor and sulfide as donor substrate. 
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2.3.2 Three cysteine synthases in the mycobacterial genome 
 
Three genes in the genome of M. tuberculosis are annotated to encode for the cysteine 
synthases CysK1 (Rv2334), CysM (Rv1336) and CysK2 (Rv0848). CysK1 shares 
~37% sequence identity with CysM and ~26% with CysK2. CysM and CysK2 have 
about 27% identity (Figure 6). The overall fold of CysK1 and CysM is similar to type II 
family of PLP-dependent enzymes. However, functional studies revealed distinct 
differences in substrate specificity. The acceptor substrate of CysK1 is OAS, which 
reacts with sulfide as a sulfur source96. CysM is dependent on OPS and 
thiocarboxylated CysO as sulfur donor97,100. CysK2 is characterized by a utilization of 
OPS and sulfide as shown in this work (paper I). In this sense CysK2 is a combination 
of CysK1 and CysM regarding substrate specificity. 
 
 
 
Figure 6: L-Cysteine synthases in M. tuberculosis. Respective substrates are indicated as well as 
sequence identity between the three enzymes. 
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2.3.3 CysK1 (Rv2334) – the classical pathway for L-cysteine 
 
De novo synthesis of cysteine in plants, archaea and many eubacteria starts with the 
acetylation of serine, catalyzed by an L-serine acetyl transferase (CysE; Rv2333). The 
product O-acetylserine is then further converted to L-cysteine in a PLP-dependent 
reaction. This step involves the elimination of acetate and the addition of H2S obtained 
during the reductive branch of the sulfur assimilation pathway by the enzyme O-
acetylserine sulfhydrylase, denoted as CysK1 (Rv2334) in M. tuberculosis96. 
The crystal structure of CysK1 has been solved and used to elucidate the structural 
basis of catalysis by this enzyme96. Similar to other PLP-dependent reactions, the 
mechanism of CysK1 follows a reaction mechanism divided into two half reactions. 
Once OAS enters the active site of the enzyme, the formation of the external aldimine 
releases the invariant lysine residue, which formed the internal aldimine in the ground 
state of the enzyme (Figure 7). 
 
 
 
Figure 7: Summarized catalytic mechanisms of CysK1, CysM and CysK2. The α-amino group of the 
acceptor substrate OPS/OAS displaces the ε-amino group of the active site lysine residue resulting in the 
formation of an external aldimine. Elimination of the OAS acetate or OPS β-phosphate leads to the 
formation of the aminoacrylate intermediate. Nucleophilic attack at the Cβ of this intermediate by sulfide 
or CysO-SH results in the formation of L-cysteine or L-cyteinyl-CysO, which is released, returning the 
enzyme to the ground state. 
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After formation of the external aldimine, a proton is abstracted by an acid-base reaction 
catalyzed by the active site lysine, which acts as base and the acetate group of OAS is 
eliminated to conclude the first half reaction with the formation of the aminoacrylate 
intermediate (Figure 7). The second half reaction is initiated by the nucleophilic anti-
addition of the incoming sulfide at the β-carbon and results in an L-cysteine-PLP 
external aldimine. Upon reprotonation of the C-α-atom by the invariant lysine, L-
cysteine is released and the internal aldimine is restored (Figure 7). The correct stereo-
specificity is ensured by the specific orientation of the aminoacrylate in the active site 
pocket, the mode of reprotonation by the invariant lysine residue and a rearrangement 
of the enzyme allowing the nucleophile to react96. 
The catalytic activity of CysK1 is competitively inhibited by the regulatory nature of a 
C-terminal tetrapeptide stretch (DFSI) of CysE suggesting the formation of a bi-
enzyme complex101. This regulatory function of the tetrapeptide stretch of CysM has 
also been observed for the bi-enzyme complex of homologues in H. influenza and A. 
thaliana102–104. Co-crystallization of CysK1 with the tetrapeptide revealed the binding 
mode of this inhibitory ligand. DFSI binds at the active site cleft between the two 
domains of CysK1 and extends to the enzyme surface. 
On basis of the CysK1-DFSI complex, high-throughput virtual screening and energy-
based pharmacophore modeling has been conducted leading to the identification of 
more potent inhibitors105,106. The binding mode of one of the strong hits was elucidated 
by X-ray crystallography. Based on the 2.0 Å structure of this enzyme-ligand complex, 
improved inhibitors in the low nM range have been developed. 
 
2.3.4 CysM (Rv1336) – an alternative cysteine synthase 
 
CysM has been identified as a phospho-L-serine sulfhydrylase in M. tuberculosis 
utilizing thiocarboxylated CysO as a sulfur donor for the subsequent de novo 
biosynthesis of L-cysteine, which clearly separates this pathway from the OAS-
dependent one (Figure 5)97,107. 
The reaction cycle of CysM, as a type II family of PLP-containing enzyme, is similar to 
that of CysK1108. The resting state of the enzyme forms an internal aldimine between 
the invariant lysine and PLP. Binding of OPS leads to the formation of the external 
aldimine, which eventually eliminates the β-phosphate from OPS resulting in the same 
aminoacrylate intermediate common in type II PLP enzymes. Burns et al. showed in 
functional studies that CysM uses a novel mode of sulfur delivery109. CysO, a small 
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thiocarboxylated protein, binds and reacts with the aminoacrylate intermediate leading 
to the formation of a covalent cysteinyl-CysO adduct in an external aldimine with the 
PLP (Figure 7). Re-protonation of the α-carbon releases the cysteinyl-CysO from the 
enzyme and the internal aldimine-ground state is restored. Cysteinyl-CysO is then 
hydrolyzed by a zinc-dependent metalloprotease (Rv1334)109. 
It is noteworthy that the oxidation-sensitive aminoacrylate intermediate in CysM is not 
prone to unspecific nucleophilic attack97. Active site closure protects the reaction 
intermediate from unspecific side reactions by maintaining a closed conformation of 
the active site providing a safe cysteine synthesis under conditions of oxidative stress, 
relevant during LTBI. The C-terminal pentapeptide of CysM (GQLWA) is instrumental 
for this conformational change, which also contributes to sulfur donor selectivity 
towards CysO100. 
Biochemical characterization of CysM and CysO revealed an alternative pathway for 
the de novo biosynthesis of L-cysteine, which by the dependence of OPS and 
thiocarboxylated CysO differs from the OAS-dependent L-cysteine synthesis. 
 
2.3.5 CysK2 (Rv0848) – paper I 
 
Besides the two previously described cysteine synthases the genome of M. tuberculosis 
encodes cysk2 (Rv0848), a third gene related to OASS sulfhydrylases, which is induced 
under oxidative stress and hypoxia59, suggesting a link of its expression to LTBI. On 
the protein sequence level, CysK2 shares about 28% sequence identity with 
mycobacterial CysK1 and CysM, respectively. 
We cloned, expressed, purified and characterized CysK2 as the third L-cysteine 
synthase in the mycobacterial genome (paper I). CysK2 uses OPS as acceptor substrate 
and sulfide as sulfur donor in a PLP-dependent reaction. The reaction mechanism of 
CysK2 resembles that of a type II family PLP-dependent enzyme and can therefore be 
subdivided into two half-reactions. The first half-reaction concludes in the formation of 
the aminoacrylate reaction intermediate after formation of the external aldimine with 
the acceptor substrate OPS (Figure 7). Thereafter L-cysteine is produced by the 
elimination of the phosphate group of OPS and the reaction of sulfide with the 
aminoacrylate. Subsequently, the internal aldimine with the invariant Lys65 is restored, 
returning the enzyme to the ground state. 
Solution studies of recombinant CysK2 by circular dichroism (CD) spectroscopy 
revealed a mixed α/β secondary structure, which compares well to that of the two 
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homologues in M. tuberculosis, CysK1 and CysM. The sequence identity between 
CysK2, CysK1 and CysM is ~28%. Distinctive motifs of PLP-dependent enzymes are 
highly conserved between the three homologues including the invariant Lys65 in 
CysK2 and the sequence stretch 201GTGGT205, which is coordinating the co-factor. 
Smaller alterations in the amino acid sequence coordinating the carboxyl group of the 
incoming substrate are manifest in CysK2 (90ESTGGTLG97) compared to CysK1 and 
CysM. Interestingly, CysK2 shows also differences at the N-terminal and C-terminal 
ends, which are missing in the two homologues (Figure 9). The characteristic 
absorption spectrum typical for class II family PLP enzymes could be observed, 
confirming the presence of PLP in CysK2 (Figure 10). 
 
 
 
Figure 8: Structure-based multiple sequence alignment of three homologue cysteine synthases in M. 
tuberculosis. 
 
After testing various putative substrates, a similar reaction to that of CysM revealed 
OPS as acceptor substrate for CysK2, which has been confirmed 
spectrophotometrically by a significant shift of the absorbance from 412 nm resembling 
the internal aldimine state110 to 465-470 nm characteristic for the aminoacrylate 
intermediate. These changes during the reaction cycle are common for PLP-dependent 
enzymes96,97,111 (Figure 9). Unlike in the case of CysM, the aminoacrylate intermediate 
is not very stable, indicating a different role of the C-terminal extension compared to 
the stabilizing role of the C-terminal residues of CysM100. 
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Figure 9: UV/Vis spectra of CysK2. The UV/Vis spectrum of CysK2 shows the specific internal 
aldimine related maximum at 412 nm (black line). Addition of 2 mM OPS results in fast enzyme-
aminoacrylate intermediate formation. Spontaneous decay of the aminoacrylate intermediate is 
demonstrated by the set of spectra recorded after 3, 6, 9, 14, 20, 30, 40 and 55 minutes following addition 
of the substrate (gray). 
 
The fast formation of the aminoacrylate could be assessed by stopped-flow 
spectrophotometry by monitoring the specific absorbance maximum at 475 nm and the 
second-order rate constant was determined to be ~ 2.5∙103 M-1s-1 that compares well 
with CysM. The phosphate release upon formation of the aminoacrylate could be 
measured in a malachite-green-based assay and revealed that CysK2 dephosphorylates 
OPS in a multiple turnover with a KM(OPS) of 233 µM and a Vmax(OPS) of 1.3 U mg-1 
at 22°C, where 1 U is defined as 1 µmol min-1. The abundance of hydroxyl ions in the 
reaction buffer leads to unspecific hydrolysis of the aminoacrylate in absence of a 
sulfur donor. This explains a higher turnover rate at higher pH111. 
This unspecific hydrolysis of the aminoacrylate has been investigated by stopped flow 
photometry and compared to the reaction in presence of the sulfur source. The presence 
of 2 mM sulfide increased the consumption of the aminoacrylate 60-times. The reaction 
product  L-cysteine has been verified by the acid-ninhydrin assay112, which allows the 
specific spectrophotometric detection of L-cysteine. Kinetic parameters have been 
determined for the sulfide driven reaction resulting in a Vmax(Na2S) of 0.5 U mg-1; 
KM(Na2S) of 374 µM and a Vmax(OPS) of 1.0 U mg-1 and KM(OPS) of 135 µM, the 
latter compare well with those obtained from the malachite green assay. 
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Arg243 in CysK2 corresponds to Arg220 of CysM (Figure 8), which was shown to be 
responsible for OPS specificity in CysM97. We have shown that Arg243 is important 
for OPS specificity for the reaction cycle in CysK2. Kinetic analysis of the 
CysK2(R243A) mutant revealed a decreased pseudo first-order rate constant in the OPS 
specific first half-reaction and a residual activity of 12% measured by determination of 
the released phosphate by the malachite green assay and about 17% in the acid-
ninhydrin assay for cysteine production. 
In conclusion, we have characterized CysK2 as a third PLP-dependent L-cysteine 
synthase in M. tuberculosis. The reaction cycle is dependent on OPS as acceptor 
substrate and sulfide as sulfur source, which is derived from the sulfur assimilation 
pathway. The substrate specificity is distinct from the two isoenzymes CysK1 and 
CysM and positions CysK2 in between the well-established routes for cysteine de novo 
synthesis. This could play a role in LTBI during which the availability of the invariant 
substrates due to redox stress is limited. OPS as acceptor substrate of CysK2 requires 
the availability of 3-phosphoglycerate, which can be allocated during hypoxia and 
oxidative stress within the alveolar macrophage by lipolysis and the subsequent release 
of glycerol, which can be phosphorylated by the glycerol kinase. These findings shed 
some light on the function of this enzyme, which so far has been elusive92. 
 
2.3.6 Targeting the cysteine biosynthesis of M. tuberculosis 
 
Mutants of M. tuberculosis depleted in CysM that are residing in alveolar macrophages 
are only attenuated in growth90 (Figure 5), hence the inhibition of only one cysteine 
biosynthetic pathways will probably not be sufficient to clear an infection. A complete 
inhibition of the L-cysteine de novo synthesis could rather be achieved by inhibiting 
three independent enzymes CysK1, CysM and CysK2 in M. tuberculosis during 
different stages of infection. 
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3. THE MYCOBACTERIAL CELL ENVELOPE 
 
The mycobacterial cell envelope displays a unique architecture, which distinguishes it 
from those of other bacterial genera. It consists of a plasma membrane, the cell wall 
core, the outer membrane and capsular polysaccharides (Figure 10). The cell wall core 
is built by peptidoglycan (PG), which is covalently attached to arabinogalactan by a 
glycosidic bond via a phosphoryl-N-acetyl glucosaminosylramnose113. Arabinogalactan 
connects via an ester bond to mycolic acids, which are one dominant component of the 
outer membrane. It harbors further non-covalently bound glycolipids, polysaccharides 
and lipoglycans, which also form the surface exposed capsule114–117. 
 
 
 
Figure 10: Schematic representation of the mycobacterial cell envelope. 
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3.1 THE CAPSULAR POLYSACCHARIDES 
 
The outer surface-exposed part of the cell envelope of mycobacteria is the capsule118, it 
coats bacteria and consists mainly of proteins and polysaccharides119–121. Three types of 
polysaccharides have been identified contributing to the capsular material: α-D-glucans 
of high molecular weight (>100 kDa) built of a core of α-1,4-glycosidic D-glucose 
polymers branching in oligoglucosides of D-arabino-D-mannan (AM) or D-mannan 
nature122. All sugars are devoid of charged modification such as acetylation and 
sulfonation. The structure of the AM is identical to that of the lipoarabinomannan 
(LAM), however deployed of the phosphatidyl-myo-inositol core. α-D-glucans 
constitute the major component of the capsule123. 
 
3.2 PIMS, LIPOMANNAN AND LIPOARABINOMANNAN 
 
Mycobacteria possess amphipathic lipoglycans, LAM, lipomannan (LM) and phospho-
myo-inositol mannosides (PIMs). They all share a phosphatidylinositol (PI) anchor 
with mannosylation extension at the 6- and 2-OH of the myo-inositol. PIMs are 
glycolipids composed of fatty acids esterified to a glycerol, which form a 
phosphodiester  with a myo-inositol124,125 (Figure 11). This phospho-myo-inositol is 
further substituted at C6 and C2-OH with α-D-mannopyranosyl (Manp) moieties to 
form PIM2, the mannosyl phosphate inositol (MPI) anchor. 
The lipid composition of the anchor is heterogeneous, with respect to number, location 
and nature of fatty acids. Four sites can be acylated at 1-OH and 2-OH of the glycerol 
unit, the 3-OH of the myo-inositol and the 6-OH of the mannose126,127. In M. 
tuberculosis, palmitic and tuberculostearic acids are the most abundant acylations. To a 
lesser extend myristic and ricinoleic acids are occurring125 (Figure 11). Intermediates of 
differently acylated PIMs accumulate in the membrane for the synthesis of higher-order 
PIMs. 
LM and LAM share both the same mannan core128, which is covalently linked to PIMs. 
The mannan backbone is composed of α-1,6-glycosidically bound Manp residues and 
flanked by α-1,2-glycosidically bound Manp (Figure 11). The core is extended by the 
condensation of a arabinan domain consisting of linear α-1,5-glycosidic 
arabinofuranose (Araf) residues, which branches in a α-3,5-glycosidic manner  to form 
two types of sugar decoration: first, linear tetra-arabinose and secondly branched hexa-
arabinose motifs129, both of which are capped by Manp in M. tuberculosis and M. 
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bovis130. PIMs, LM and LAM play a key role in arresting lysosomal fusion and 
endosomal fusion with the phagosome131. 
 
 
 
Figure 11: Cell wall components based on phospho-myo-inositol mannosides (PIMs) (a) schematic 
representation of the polysaccharides linked to the PIM to form various lipoglycans of the cell wall (b) 
fatty acids (R1-4), which anchor the PIM in plasma membrane. 
 
3.3 ARABINOGALACTAN 
 
Arabinogalactan is exclusively built of furanose sugars and tethers the mycolic acids to 
the PG layer. The galactan domain is composed of 30 Galactofuranose (Galf) residues 
in β-1,5- and β-1,6-glycosidic bonds, three arabinan domains containing ~30 Araf 
residues α-1,3-, α-1,5- and β-1,2-glycosidically branching from the galactan at sugar 
positions 8, 10 and 12 and a spacer at the reducing end covalently linked to the PG via 
5-D-Galf-1,4-L-Rhap-1,3-D-GlcNAc129,132. 
 
3.4 PEPTIDOGLYCAN 
 
Peptidoglycan (PG) is a complex polymer forming the rigid layer of the cell wall, 
providing cell shape and protection against shere stress and osmotic pressure117,133,134. 
Together with the arabinogalactan layer it forms the cell wall core. To date, the 
orientation of the glycans of the PG layer is controversal. Most of the experimental data 
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suggest the glycan strands to be oriented in parallel to the cell surface, however,  a 
second model proposed a perpendicular orientation of the glycan strands to the cell 
surface134–136. The PG of M. tuberculosis belongs to the classification A1γ similar to 
that of E. coli and B. subtilis137. It is composed of a backbone of alternating N-acetyl-α-
D-glucosamine (GlcNAc) and muramic acids (Mur), which can be modified in various 
ways, however they are acylated by glycolic acid rather than acetylated138–140. Mur 
connects via the 6-OH to the arabinogalactan layer129,134,141. The linar polysaccharides 
formed by alternating units of Mur and GlcNAc are dispersed by peptide side chains of 
L-alanyl-D-isoglutaminyl-meso-diaminopimelyl-D-alanine. The peptide stems are in 
turn covalently linked to the Mur. Two peptide stems from adjacent saccharide back-
bones can be heavyly cross-linked. Up to 80% of the PG peptide stems are cross-linked 
in M. tuberculosis142, whereas in E. coli only 50% of the PG peptide stems display the 
same feature135. The amino acids of the peptide stem can be further modified by 
amidation of the glutamyl and diaminopimelinyl residues134. Two different types of 
cross-links have been characterized, which are catalyzed by different transpeptidases: 
3-4 cross-links, containing a D-alanyl-D-aminopimelinyl peptide bond formed by 
penicillin-binding proteins (PBPs) and 3-3-cross-links with different chirality between 
the L- and D-center of two adjacent diaminopimelic acids that are catalyzed by L,D-
transpeptidases143 (Figure 12). 
 
Figure 12: Chemical structure of a PG unit. MurNAc is condensed via a lactoyl linker to the tripeptide L-
alanyl-D-isoglutaminyl-meso-diaminopimelic acid, which in turn is involved in cross-linking to the 
neigbouring peptide stem of the adjacent sugar-backbone. 
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3.4.1 Synthesis and remodelling of peptidoglycan 
 
The initial step of PG synthesis is cytoplasmatic and requires the activation of N-
acetylglucosamine and muramic acid to form their respective UDP-forms144,145 (Figure 
13). Thereafter the pentapeptide stem is built up on the UDP-MurNAc by sequential 
steps. This process is ATP-driven and involves the proteins of the Mur operon. The 
resulting UDP-MurNAc-pentapeptide is therafter decaprenylated (lipid I) and 
condensed with UDP-GlcNAc by MurG to form the membrane-anchored lipid II 
intermediate. Lipid II is flipped across the membrane and upon insertion in the growing 
glycan chain of the sacculus, the decaprenyl anchor is released146,147 (Figure 13). 
The cross-link formation within the PG sacculus subunits is catalysed by D,D-
transpeptidation, forming 3-4-connections (DAP-D-Ala) and L,D-transpeptidases 
forming 3-3-cross-links148 that stabilize the PG layer of the bacilli149 (Figure 13). PBPs 
are globular proteins located on the exterior of the plasma membrane. They are grouped 
into high- and low- molecular weight PBPs. Four PBPs have been characterized as β-
lactam targets in M. tuberculosis150. The M. tuberculosis genome encodes for five 
isoenzymes of L,D-transpeptidases, all of which have been identified as off-targets for 
β-lactam treatment151,152. 
During cell division and bacterial growth, PG remodelling requires the cleavage of 
covalent bonds to allow the sacculus to grow without only thickening it144. This follows 
a concerted mechanism of hydrolases of different nature including D,D- and L,D-
endopeptidases (D,D-EPases, L,D-EPases), transglycosylases (RpfBs)153, amidases154 
and NlpC/p60 proteins155–157. 
The release of PG cleavage products, also referred to as muropeptides, has been known 
for some time to result in the activation of immune response. NOD1 and NOD2 
receptors have been shown to interact with PG fragments. Their leucine-rich repeat 
domain is responsible for ligand recognition. The smallest fragment recognized by 
NOD1 is iE-Dap, whereas NOD2-mediated signaling is activated by muramyl 
peptides158. 
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Figure 13: The synthesis and condensation of a new PG strand into the existing network. PG building blocks are 
synthesized in the cytoplasm, and subsequently linked to undecaprenyl phosphate and flipped across the plasma membrane. 
A glycosyltransferase (GTase) catalyzes the polymerization of the PG. Thereafter, the building unit is attached to the 
sacculus by a D,D-transpeptidase (D,D-TPase). Peptides are trimmed by D,D-, L,D-and D,L-carboxypeptidases (CPases). 
Cross-links are cleaved by the D,D-and L,D-endopeptidases (EPases). L,D-transpeptidases (L,D-TPases) are required for the 
formation of L,D-cross-links (3-3). 
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3.4.2 The Rip-family 
 
In the Mycobacterium marinum-zebrafish model system two genes denoted as iipA 
(ripA) and iipB (ripB), which show partial homology, have been identified to be 
involved in invasion of host macrophages and intracellular persistence. Upon deletion 
of the iipA locus, the pathogen loses virulence and shows decreased survival within the 
host macrophages. Additionally, increased sensitivity to ciprofloxacin, erythromycin 
and the first-line drug RIF and atypical septum formation has also been observed. 
Interestingly, this distinct phenotype could be rescued by complementing with the M. 
tuberculosis gene Rv1477 (RipA), suggesting a similar function of the Rv1477-
Rv1478-operon155. 
RipA and RipB contain a NlpC/p60 domain156,157. Two additional NlpC/p60 proteins 
are encoded in the mycobacterial genome, RipC (Rv2190c) and RipD (Rv1566c) 
(Figure 14 and 15). NlpC/p60 hydrolases are characterized as specific PG hydrolases 
involved in PG remodelling and cell division. NlpC/p60 proteins were characterized 
first as autolysins LytE and LytF of L. monocytogenes proteins p60 and p45. This 
family also includes the E. coli membrane-associated lipoprotein NlpC (termed as 
NlpC/p60 proteins), which possesses a conserved amino-terminal cysteine. Members of 
this family are characterized as endopeptidases hydrolysing the D-glutamyl meso-
diaminopimelate linkage in the PG159. Multiple paralogues have been identified in most 
bacteria, which underlines their importance in PG remodelling and cell division160. 
 
 
 
Figure 14: The four proteins of the Rip-family in M. tuberculosis. Sequence identities based on the 
NlpC/p60 core domain are indicated. 
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3.4.3 RipA (Rv1477) and RipB (Rv1478) – paper II 
 
RipA (Rv1477) identified as a binding partner of RpfB and RpfE (resuscitation-
promoting factors B and E) localizes at the septum region of dividing bacteria together 
with RpfB116. RipA and RipB proteins belong to the superfamily of NlpC/p60 
hydrolases (Figure 14 and 15). 
 
Figure 15: (a) modular organization of NlpC/p60 homologues in M. tuberculosis. RipA and RipC contain 
an additional N-terminal domain. (b) Structure-based multiple sequence alignment. RipA (PDB:3PBC) 
was used as a reference structure; secondary structure is indicated: β-sheet ( ), helix ( ). 
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Since RpfB and RpfB homologues in M. tuberculosis contain a lysozyme-homologue 
domain161 and RipA contains a catalytically active peptidase domain, the RipA-RpfB 
complex can be considered as a putative PG degradation machinery combining the 
proposed glycosidase activity of RpfB with the peptidase activity of RipA. PBP1 
(Rv0050) also interacts with the C-terminal NlpC/p60 domain of RipA, hence the 
formation of a PG-remodelling machinery of hydrolases, transglycosylases and 
transpeptidases were suggested, coordinating the cell wall remodelling162. 
RipA and RipB are encoded in the same operon and most likely expressed 
simultaneously. RipA is composed of two distinct domains: a so far uncharacterized N-
terminal domain and the C-terminal NlpC/p60 domain. RipB is an NlpC/p60 domain 
protein without larger additional domains. Both proteins display a signal sequence at 
the N-terminus, which allows them to be transported to the periplasmic space. 
Our interaction studies between RipA, RipB and their suggested substrate clearly 
strengthened their proposed localisation in the PG meshwork (Figure 16). Purified 
proteins have been tested for binding HMW-PG in a binding assay154. RipA and RipB 
accumulate in the insoluble HMW-PG. 
 
 
Figure 16: PG-binding experiment. (a) Fractions from the binding assay using RipAc (RipA-NlpC/p60; 
residues 260–472) and RipB proteins. (b) RipAc(Cys383Ala) mutant binding to HMWPG. (c) Truncated 
proteins RipActr and RipBtr. (d) BSA binding to HMWPG. (e) Lysozyme binding to HMWPG. 
 
Both proteins show catalytic activity in cleaving defined soluble PG fragments e.g. γ-
D-glutamyl-meso-diaminopimelic acid (iE-Dap) or L-alanyl-γ-D-glutamyl-meso-
diaminopimelic acid (tri-Dap) (shown in paper II). The exact cleavage position could 
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be determined to be the peptide bond between iE-Dap. A more detailed proposal for the 
enzymatic mechanism has been described157 (Figure 17). 
 
 
 
Figure 17: Reaction scheme following the formation of isoindole derivatives based on the catalytic 
activity of RipA and RipB. The enzymatic reaction is performed prior to the o-phthalaldehyde 
derivatization. 
 
Full-length RipA and RipB were active on PG fragments as substrates in vitro. 
Similarly, RipA-NlpC/p60 (residues 260–472) showed activity on the PG fragments.  
After the assays were completed, full-length RipA, RipA-NlpC/p60 domain (residues 
260–472) and RipB proteins were retained and tested for integrity by SDS-PAGE. No 
proteolytic cleavage of the proteins occurred during incubation and assays. These 
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findings suggest that the proteolytic removal of the N-terminal segment of RipA-
NlpC/p60 (residues 263–283) suggested by others157 is not necessary for catalytic 
activity and thus argues against an inhibitory role of this particular fragment. 
The assay is based on a coupled reaction combining the enzymatic reaction to the 
synthesis of isoindole derivatives upon the reaction of o-phthalaldehyde with the 
primary amines of the product. This reaction can be monitored photometrically by 
which the readout can be directly related to the amount of primary amines in the 
sample. 
High-molecular-weight (HMW) PG from B. subtilis has been used to further assess the 
hydrolase activity on the insoluble polymer. Interestingly, only RipA (C domain) 
showed a defined activity in the conditions tested in the experiment. HMW-PG from 
Staphylococcus aureus is not cleaved by the substrate-specific hydrolases of the 
NlpC/p60 protein RipA demonstrating substrate specificity towards PG similar to the 
mycobacterial substrate. 
The 3D-structures of RipA (C-terminal domain; residues 260–472) and RipB (30–241) 
have been determined to 1.38 Å and 1.6 Å, respectively (Figure 18) (paper II). Both 
structures display the classical fold of NlpC/p60 proteins by a six stranded anti-parallel 
β-sheet packed against 3 α-helices. Both proteins show significant differences in the N-
terminal segment of the respective protein construct (Figure 18 and 19). In RipB, this 
segment (residues 30–97) forms two α-helices, which clasp around the core. RipA 
displays a different feature, where the N-terminal segment forms in contrast a β-hairpin 
followed by a helical stretch (residues 260–321). 
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Figure 18: Stereo image of RipA (a) and RipB (b). Shown is the overall structure in cartoon 
representation. The catalytic NlpC/p60 domain is displayed in gray colour, the N-terminal segment in 
black. 
 
The catalytic residues of the papain-like cysteine proteases are retained in RipA and 
RipB in similar 3D arrangement. Corresponding to Cys25, His159 and Asn175 in 
papain, RipB displays Cys152, His201 and Glu213 and RipA Cys383, His432 and 
Glu444. The active sites of RipA and RipB are shielded by the N-terminal segment, 
which falls back into the active site cleft. In the crystal structure, about 25 residues 
shield the binding groove for the incoming substrate (Figure 18). Probably, this 
segment adopts a different orientation in solution. Structural differences between RipA 
and RipB with respect to their N-terminal segments and surrounding of the binding 
groove could explain the differences in activity on HMW-PG. 
Other members of the NlpC/p60 family display only 10-12% similarity to RipA and 
RipB. This is explained by the high variance in the N-terminal modules of the 
homologue proteins, which are often occurring. These N-terminal domains may direct 
their specific interaction with PG and possibly other cell wall components160 
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(Figure19). The E. coli enzyme Spr was the first which has been characterized as a 
NlpC/p60 protein, revealing the similarity to papain-type cysteine proteases163. Spr and 
RipD are the only available high resolution structures of NlpC/p60 proteins, which do 
not carry additional N-terminal extensions (Figure 19). The N-terminal segments of 
RipA and RipB are unique in the family of NlpC/p60 proteins. So far, only one 
structure of the Bacillus cereus YkfC NlpC/p60 family protein has been determined in 
complex with the PG-derived dipeptide L-alanyl-D-glutamic acid164. 
 
 
 
Figure 19: Domain organization of NlpC/p60 like proteins. The catalytic core is coloured in black, the 
variable N-terminal domains or smaller extensions are shown in gray. 
 
3.4.4 RipD (Rv1566c), an NlpC/p60-like protein – paper III 
 
RipD is an NlpC/p60 family protein encoded by the gene Rv1566c with about ~50% 
sequence similarity (residues 38–169) to the respective domains of RipA and RipB. In 
contrast to these NlpC/p60 proteases, the active site residues Cys383 and His432 are 
replaced in RipD by an alanine and a serine, respectively. A distinct C-terminal 
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pentapeptide (PVQQA)-repetitive extension protrudes from the NlpC/p60 core, which 
is unique for RipD homologues. 
We determined the crystal structures of the core domain of RipD  (residues 38–167) to 
1.54 Å and a variant containing two pentarepeats to 1.2 Å resolution by molecular 
replacement using the homologue from M. avium as search model (PDB-ID:3GT2) 
(Figure 20). 
 
 
 
Figure 20: (a) Stereo-cartoon representation of RipD depicting the antiparallel β-sheet packed against 3 
shorter α-helices common for NlpC/p60 proteins. (b) Superposition of RipA and RipD. Active site 
residues as well as surrounding residues are shown as gray (RipD) and black (RipA) sticks. The core 
domain in light gray shown in the background represents a cartoon of RipD. 
 
Similarly to the homologues RipA and RipB in M. tuberculosis, the core domain of 
RipD folds in a five stranded anti-parallel β-sheet packed against three shorter α-
helices. The structure of a related protein from M. avium has also been solved 
(PDB:3GT2, Ramyar et al., unpublished). The PG-binding in RipD is proposed to take 
place in an elongated groove similar to those found in RipA and RipB. Direct 
comparison of the full-length RipD (residues 38–230) comprising the pentapeptide 
repeat segment and the RipD core domain (residues 38–167) in solution by CD resulted 
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in an increase of random coil content, suggesting that the repeat does not adopt a 
defined secondary structure, which is a common property of perfect repeats. 
In contrast to RipA and RipB, RipD does not show activity on PG fragments. However, 
the NlpC/p60 core domain retains the ability to bind PG as shown in paper III. This 
interaction is altered by the presence of the C-terminal pentapeptide repeat, rendering 
the full-length RipD less potent in binding to PG. In a binding experiment with isolated 
cell wall complex containing PG and arabinogalactan, the interaction was not altered 
suggesting no direct interaction with the arabinogalactan. 
RipD-like proteins with amino acid replacements in the active site incompatible with 
catalysis are not very common. They are only found in mycobacterial genomes and 
closely related Segniliparus ssp. Interestingly, the occurrence of changes in the active 
site and C-terminal repeat is exceptional for mycobacterial species. In M. smegmatis, 
M. abcessus, M gilvium and M. vanbaalenii RipD-like proteins do not contain C-
terminal repeats. Other cell envelope resident proteins have also been characterized 
carrying a proline-rich repeat e.g. the flagellar assembly protein of Thiorhodococcus 
drewsii or the heme exporter protein of Yersinia spp. Surprisingly, a 
mycobacteriophage protein also displaying a PVQXX repeat has been found165. 
We described RipD as an NlpC/p60 domain containing protein, which lost the catalytic 
activity to cleave the peptide stem of mycobacterial PG. The PG-binding however is 
retained and modulated by the presence of the C-terminal pentarepeat segment. RipD is 
the first example of an NlpC/p60 domain that evolved to a non-catalytic PG-binding 
protein. The 61 residue-long unstructured C-terminal pentapeptide repeat results in 
weaker interaction with PG in vitro, suggesting that the repeat segment modulates the 
RipD cell wall interaction. Possibly, the pentarepeat domain is involved in protein 
interaction between RipD and other periplasmic proteins or with other cell wall 
components166. 
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Table 1: Occurrence of pentapeptide repeats in mycobacterial species and closely related Segniliparus 
ssp. The nature of the respective repeat domain is explicitly given. 
Species (Strain) Functional Annotation Uniprot ID Length (aa) 
Repeat 
character 
N/L¤ 
M. tuberculosis (H37Rv) invasion-associated protein O06624 230 10/5 
M. tuberculosis (H37Ra)# putative invasion protein A5U2S3 230 10/5 
M. bovis (BCG and AF2122/97) putative invasion protein Q7VEY5 230 10/5 
M. ulcerans (Agy99) invasion protein A0PNZ9 259 16/5 
M. marinum (ATCC BAA-535) invasion protein B2HQ87 259 16/5 
M. avium (k10) hypothetical protein Q740S0 316 19/5+3/4 
M. avium (104) NlpC/p60 protein A0QHK2 289 21/5+3/4 
M. leprae (TN) secreted p60 protein Q9CC67 212 1/5 
M. abscessus (ATCC 19977) hypothetical protein B1MBD4 184 none 
M. sp. (KMS and MCS) NlpC/p60 protein Q1B8K4 204 none 
M. smegmatis (MC2 155) putative invasion protein A0QXZ3 220 none 
M. gilvum (PYR-GCK) NlpC/p60 protein A4TAN6 214 none 
M. vanbaalenii (PYR-1) NlpC/p60 protein A1T9C5 208 none 
Segniliparus rotundus (DSM 44985) NlpC/p60 protein D6ZAC6 164 none 
Segniliparus rugosus (ATCC BAA974) NlpC/p60 protein E5XV46 164 none 
#… and other M. tuberculosis strains; RGTB327; RGTB423; F11; CDC1551; Haarlem (draft); strain C. 
¤… N, number of repeats; L, length of one repeat unit 
 
3.5 L,D-TRANSPEPTIDASES IN M. TUBERCULOSIS 
 
Since M. tuberculosis expresses a significant number of class A lactamases167, β-
lactams were not considered as a promising medication against TB. However, a success 
in treatment of TB has revived the interest in a combination therapy with potent 
lactamase inhibitors of the clavulanate family and carbapenem-type β-lactams. A 
bactericidal effect has been proven, not only against growing M. tuberculosis, but also 
against the non-replicating forms168. Additionally, several of those combinations have 
shown to be active against XDR strains167,168. 
Carbapenem class β-lactams are active on transpeptidases necessary for the assembly of 
PG in the periplasmic space of M. tuberculosis and other species152.  Two classes of 
transpeptidases have been described. D,D-transpeptidases of the penicillin-binding 
protein class necessary for the formation of 3-4 cross-links and L,D-transpeptidases, 
which link the peptide stems between the two adjacent Dap residues (3-3 cross-links). 
The 3-3 cross-link is the predominant form during the persistent state of M. 
tuberculosis142,152. L,D- and D,D-transpeptidases are structurally not related and 
function via a different catalytic mechanism148,169. 
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The mycobacterial genome H37Rv encodes for the five homologs LdtMt1 to LdtMt5 of 
which LdtMt2 (Rv2518c) has been reported to be essential for virulence. Inactivation of 
the LdtMt2 gene leads to attenuation and increased susceptibility to clavulanate/lactam 
treatment in vitro and in mice152. All homologues of M. tuberculosis transpeptidases are 
susceptible to penem class β-lactams and these findings have triggered an interest in 
these enzymes in recent years. This is also reflected in crystal and NMR structures for 
L,D-transpeptidase from M. tuberculosis and other species being published by 5 
different groups within a six months period170–175. Crystal structures of the enzyme with 
bound antibiotics are expected to open up the route for improved TB therapy176 by 
providing templates for design of new inhibitors. 
 
3.5.1 The structure of LdtMt2 – paper IV 
 
LdtMt2 is a protein composed of a small intracellular segment (residues 1–17) followed 
by a transmembrane domain (residues 18–34) and a periplasmic part (residues 35–
408). The catalytic domain (residues 250–408) could be well predicted from sequence 
alignment with homologues in M. tuberculosis and Corynebacterineae that also contain 
L,D-transpeptidases. We assessed the domain border of the residues 34(55)–250 by 
sequence comparisons to homologues, domain border prediction177 and secondary 
structure prediction using Jpred178 resulting in a predicted three domain organization, 
hereafter referred to as domain A, B and C (Figure 21). We cloned 13 and purified 10 
constructs and were able to solve the crystal structure of the construct comprising the 
BC domain by Se-SAD phasing to 1.86 Å and subsequently the structure of the AB 
module by molecular replacement using the B domain of the BC module structure as a 
search model as described in paper IV (Figure 21). The BC module comprises the 
catalytic domain of the well characterized ErfK/YbiS/YhnG fold and an 
immunoglobulin (Ig)-like domain. The core of the transpeptidase domain folds into a β-
sandwich formed by two anti-parallel β-sheets, which compares well to structure of the 
corresponding enzymes in E. faecium (PDB:1ZAT)169 and B. subtilis (PDB:1Y7M)179 
with r.s.m.d. of 1.9 Å and 1.6 Å, respectively. The active site residues of LdtMt2 are 
Cys354 and His336 and correspond to Cys442 and His421 in the E. faecium 
homologue. A lid-like structure comprised of two anti-parallel β-strands closing the 
active site cleft by large aromatic residues of the lid (Tyr298, Tyr308, Tyr318) and of 
the core domain (Tyr330, Phe334 and Trp340). 
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Figure 21: (a) Modular organization of LdtMt2 (Rv2518c). (b) Cartoon representation of the BC and the 
AB domain. (c) Reconstruction of the complete periplasmic part. Active site lid is indicated. 
 
Both the A domain and the B domain have the same topology, corresponding to the c-
type Ig fold. A structural alignment using the DALI algorithm revealed the closest 
structural homologous to be the periplasmic copper-resistance protein from P. syringae 
(PDB:2C9R)180, the N-terminal domain of a amylase of Halothermothrix orenii 
(PDB:3BC9)181 and a mannanase from Cellolumonas fimi (PDB:2X2Y)182. Functional 
relation to the copper-resistance protein is excluded since the copper-coordinating 
residues are missing. A relation to the other two proteins being involved in 
polysaccharide metabolism could be relevant due to the presence of glycans in the cell 
envelope of M. tuberculosis suggesting LdtMt2 is interacting with the glycan chains via 
the A and B domain. There are four surface-located threonine residues that are 
conserved between the amylase and the A domain of the LdtMt2181. 
The extramembrane part of the LdtMt2 shows a three domain organization which we 
were able to reconstruct (Figure 21), whereas others missed one of the Ig domains168. 
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Our model of the entire extramembrane part of the enzyme was confirmed by the 
structure determination of a three-domain construct comprising the A, B and C 
domains174. The three domain structure of LdtMt2 extends about 80 Å from the plasma 
membrane excluding a stretch of 20 missing amino acids at the N-terminus. This places 
the catalytic domain in a defined vicinity to the membrane. Interestingly, among the 
remaining four L,D-transpeptidases encoded in the mycobacterial genome Rv0116c 
LdtMt1 and Rv1433 contain only two domains, the C-terminal catalytic domain and the 
N-terminal Ig-like domain183. Both proteins show significant sequence identity to the 
BC domain of LdtMt2. Rv0483 and Rv0192 have a three domain organization. They do 
not only show sequence identity to the BC domain, but also to the A domain (35% for 
Rv0483 and 18% for Rv0192).  
Thus, two groups of L,D-transpeptidases are present in M. tuberculosis, those 
comprising three domains and those with two domains. Differences in the number of 
domains position the catalytically active C-terminal domains at different distances from 
the membrane and thereby follow the multilayered architecture of PG. 
 
3.5.2 LdtMt2-complex with β-lactam antibiotics 
 
The formation of an acyl-enzyme complex between L,D-transpeptidases and β-lactams 
has been demonstrated with the homologue from B. subtilis172.  We and others showed 
that LdtMt2 clearly interacts with penam and penem, cephalosporin class β-
lactams167,171.  
 
Table 2: Covalent adducts formed with β-lactam type antibiotics imipenem and ampicillin. 
Protein construct, 
MW (Da) -lactam, MW (Da) Detected mass (Da) Mass difference (Da) 
LdtMt2 periplasmic 
segment (34-408) 
40073.8 
Imipenem, 299.3 40372.6 298.8 
LdtMt2 BC-module 
(149-408), 
28481.7 
Imipenem, 299.3 28780.1 298.4 
Ampicillin, 349.4 28831.7 350.0 
 
Development of carbapenems (penem class) for TB treatment has recently raised 
considerable interest since these drugs are uniformly active against MDR-TB and 
XDR-TB and kill both exponentially growing and dormant forms of the bacilli, in 
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association with the lactamase inhibitor clavulanic acid168. All five L,D-transpeptidases 
of M. tuberculosis have been tested for their activity in cross-linking PG peptide stems 
and for β-lactam acylation. The formation of the acyl-enzyme complex has been seen 
for all mycobacterial homologues LdtMt1-5171,176,184. Crystal structures of LdtMt1 and 
LdtMt2 in complex with imipenem and meropenem, both members of the penem class of 
β-lactams, i.e. as the enzyme-acyl adduct, have been obtained. However, none of the 
adducts could be modeled completely due to missing electron density suggesting that 
large parts of the drugs are disordered in the binding site. This indicates that residues of 
the binding site do not significantly contribute to β-lactam selectivity. This conclusion 
is also strengthened by the formation of acyl-enzyme adducts with antibiotics of 
various β-lactam classes. In all these cases almost no interactions with the surrounding 
residues are present173,183. Nevertheless, based on the structural and biochemical 
information new lead compounds might be developed based on the core β-lactam 
scaffold. 
 
3.6 TRAGETING THE CELL WALL – AN OUTLOOK 
 
The importance of the cell wall makes it a well exploited target of a broad range of 
antibiotics. Potent inhibitors and first-line antibiotics have been developed such as INH, 
EMB, RIF and PYR, which target biosynthetic pathways of the mycobacterial cell wall. 
Currently, an emphasis is on the development for new alternatives of INH, an InhA 
inhibitor, which arrests mycolic acid synthesis. Recently, substituted triclosan 
derivatives  have been shown to potently inhibit bacterial growth tested against INH-
resistant strains of M. tuberculosis185. 
A second group of antimycobacterial drugs targeting the cell envelope are the 
arabinofuranosyltransferase inhibitors e.g. EMB. They disrupt the biosynthesis of AG 
and LAM and evoke an accumulation of β-D-arabinofuranosyl-P-decaprenol186,187. 
Here, EMB has also been used as a scaffold for the development of new anti-
mycobacterial therapeutics. SQ09 has been synthesized as an analogue which displays 
promising pharmacokinetics, even in EMB-resistant strains188. Surprisingly, SQ09 does 
not inhibit the arabinosyltransferase, but rather a membrane transporter of TMM, 
MmpL3, preventing the incorporation of mycolic acids into the mycobacterial cell 
wall189. 
β-lactam antibiotics are probably the oldest group of antimicrobial drugs which have 
been administered during TB infection. Their prime target is the transpeptidase module 
 40 
of penicillin binding proteins (PBPs), that cross-link PG subunits by D,D-
transpeptidation, forming 3-4 linkages (DAP-D-Ala) that stabilise PG layer of the 
bacilli149,190. β-lactams mimic the newly formed peptide bond and are potent inhibitors 
counteracting the cross-link formation. This mechanism of attacking a key step in 
bacterial cell wall synthesis renders β-lactams a versatile class of antibiotics whose 
numerous members with various chemical and pharmacological properties exert 
bactericidal effects on a broad spectrum of bacterial pathogens. 
However, there are two main reasons why β-lactam antibiotics have not been 
considered to be appropriate for the treatment of TB: M. tuberculosis produces a 
chromosomally encoded β-lactamase167,191 and secondly, it has been shown that cross-
links through 3,3-linkages (DAP-DAP) are of vast importance in mycobacterial 
PG142,143. These DAP-DAP linkages are produced by L,D-transpeptidases (LdtMt1 and 
LdtMt2) rather than classical PBPs – a very different class of enzyme with a catalytic 
cysteine instead of a serine in the active site152,171. However the formation of the β-
lactam acyl-enzyme complex has been shown for all mycobacterial homologues LdtMt1-
5
171,176,184. Since the interaction is mainly driven by the covalent bond between drug and 
enzyme and not by the residues forming the surrounding of the active site, the rational 
design of new leads based on the β-lactam scaffold specific for L,D-transpeptidases is 
of high interest. 
RipA has been identified as a potential drug target. A RipA knock-out showed a 
distinct phenotype rendering the bacilli with impaired growth and increased 
susceptibility towards ciprofloxacin, erythromycin and the first-line drug RIF155. 
According to the gene knock-out data, a potential inhibitor would probably be 
administered in a combination therapy regimen i.e. with RIF to successfully achieve 
bacterial clearance. The biochemical and biophysical characterization will guide the 
path towards the development of new inhibitors targeting RipA. 
Taken together the efforts in characterizing new potential drug targets provide 
frameworks for a structure-based approach towards new leads against M. tuberculosis, 
which might be developed into new drug candidates. 
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